- Home
- FRMI vs HOLX Comparison
FRMI vs HOLX Comparison
Compare FRMI & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRMI
- HOLX
- Stock Information
- Founded
- FRMI 2025
- HOLX 1985
- Country
- FRMI United States
- HOLX United States
- Employees
- FRMI N/A
- HOLX N/A
- Industry
- FRMI Real Estate Investment Trusts
- HOLX Medical Electronics
- Sector
- FRMI Real Estate
- HOLX Health Care
- Exchange
- FRMI Nasdaq
- HOLX Nasdaq
- Market Cap
- FRMI 14.1B
- HOLX 16.5B
- IPO Year
- FRMI 2025
- HOLX 1990
- Fundamental
- Price
- FRMI $18.24
- HOLX $74.21
- Analyst Decision
- FRMI Strong Buy
- HOLX Hold
- Analyst Count
- FRMI 7
- HOLX 15
- Target Price
- FRMI $30.86
- HOLX $79.64
- AVG Volume (30 Days)
- FRMI 4.9M
- HOLX 5.2M
- Earning Date
- FRMI 11-10-2025
- HOLX 11-03-2025
- Dividend Yield
- FRMI N/A
- HOLX N/A
- EPS Growth
- FRMI N/A
- HOLX N/A
- EPS
- FRMI N/A
- HOLX 2.49
- Revenue
- FRMI N/A
- HOLX $4,100,500,000.00
- Revenue This Year
- FRMI N/A
- HOLX $6.23
- Revenue Next Year
- FRMI N/A
- HOLX $5.37
- P/E Ratio
- FRMI N/A
- HOLX $29.78
- Revenue Growth
- FRMI N/A
- HOLX 1.74
- 52 Week Low
- FRMI $16.30
- HOLX $51.90
- 52 Week High
- FRMI $36.99
- HOLX $80.31
- Technical
- Relative Strength Index (RSI)
- FRMI N/A
- HOLX 66.79
- Support Level
- FRMI N/A
- HOLX $74.07
- Resistance Level
- FRMI N/A
- HOLX $74.66
- Average True Range (ATR)
- FRMI 0.00
- HOLX 0.25
- MACD
- FRMI 0.00
- HOLX -0.20
- Stochastic Oscillator
- FRMI 0.00
- HOLX 39.51
About FRMI Fermi Inc.
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.